Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > REGULATORY
REGULATORY
- MHLW to Set Up Panel to Promote Biosimilars as Early as Next Year: Official
August 9, 2022
- E Keppra Now Eligible for Health Coverage for Status Epilepticus
August 8, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- MHLW Panel OKs Onoact for Pediatric Tachyarrhythmia and More Drugs
August 5, 2022
- Evaluate Shionogi COVID Pill Based on Omicron Symptoms: Komeito Lawmakers
August 5, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Now in Line for Approval
August 4, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- Japan OKs FY2023 Budget Guidelines, 560 Billion Yen Cap for Social Security Cost Rise
August 1, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Clear MHLW Panel, September Approval Likely
August 1, 2022
- MHLW Flags Hoarding of Acetaminophen, Ayumi Stops Supply of 2 Dosage Forms
August 1, 2022
- PMDA Reviewing Safety Risks for Plaquenil, Cyramza
August 1, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
- Online Submissions for Partial Changes of Generics to Start from October
July 29, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…